10161773Feasibility Study of a Predictive Algorithm for Cervical Cancer Risk Stratification and PreventionActiveFeasibility StudiesInnovate UKThis feasibility study will develop and validate an innovative predictive algorithm aimed at transforming cervical cancer prevention. Despite screening programmes, cervical cancer affects approximately 3,200 women annually in the UK. While HPV infection is the primary cause, around 90% of infections clear naturally within two years. The critical challenge we are looking to address is identifying which infections will persist and potentially develop into cancer. Daye will address this challenge by creating an algorithm that integrates multiple data types to assess individual risk for HPV persistence and cervical cancer progression. What distinguishes our approach is the incorporation of vaginal microbiome analysis, an emerging biomarker with established links to HPV persistence and cervical carcinogenesis. This will be combined with traditional risk factors including HPV strain, lifestyle elements and comprehensive medical history. The vaginal microbiome represents a particularly promising and modifiable intervention target. Research demonstrates that certain microbiome compositions significantly impact HPV clearance rates and inflammation pathways linked to cancer development. By incorporating this novel biomarker alongside established risk factors, we aim to create more precise, personalised risk assessments. Our 12-month feasibility study will first develop a prototype algorithm using existing datasets to create comprehensive risk profiles. We will then validate this approach using real-world data from patients enrolled in the National HPV screening programme, assessing the algorithm's accuracy in predicting HPV persistence. The study will determine whether this integrated approach can provide clinically meaningful risk stratification, enabling the creation of personalised prevention plans. We will also explore implementation pathways within existing screening programmes, establish regulatory requirements, and develop a commercialisation strategy. If successful, this innovation could transform cervical cancer prevention from passive surveillance to active intervention. The algorithm would help clinicians identify high-risk patients and recommend targeted interventions focused on modifiable factors, including vaginal microbiome health. This represents an important step toward more personalised, proactive healthcare that could benefit thousands of women in the UK and millions worldwide.